Mycosis Fungoides clinical trials
The registry lists 447 studies for Mycosis Fungoides across more than 10 countries. 42 are recruiting or about to start. 100 of them are mainly about Mycosis Fungoides (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Mycosis Fungoides studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (51) · Fred Hutchinson Cancer Center (32) · Northwestern University (18) · City of Hope Medical Center (18) · Mayo Clinic (18) · M.D. Anderson Cancer Center (16) · Memorial Sloan Kettering Cancer Center (13) · European Organisation for Research and Treatment of Cancer - EORTC (12)
What is being tested here
Drugs under test in Mycosis Fungoides studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Mogamulizumab | 2 | 0 | 6 |
| Cemiplimab | 2 | 0 | 3 |
| Cyclophosphamide | 1 | 1 | 16 |
| Brentuximab Vedotin | 1 | 1 | 9 |
| Lenalidomide | 1 | 1 | 9 |
| Bexarotene | 1 | 1 | 9 |
| Methoxsalen | 1 | 1 | 4 |
| Duvelisib | 1 | 0 | 2 |
| Imiquimod | 1 | 0 | 2 |
| Cosibelimab | 1 | 0 | 1 |
Drug classes tested here Immune checkpoint inhibitors 4 open · Tyrosine kinase inhibitors (TKIs) 4 open · JAK inhibitors 4 open · Alkylating agents 1 open · Antimetabolites 49
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Feb 2027TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides · Phase 3 · Assistance Publique - Hôpitaux de Paris
- Nov 2026JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas · Institute of Hematology & Blood Diseases Hospital, China
- Dec 2026Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome · Stanford University
- Dec 2026A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma · Peking University First Hospital
- Jan 2027A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab · City of Hope Medical Center
- Jan 2027Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides · M.D. Anderson Cancer Center
- Feb 2027Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome · Washington University School of Medicine
- Mar 2027Photopheresis in Early-stage Mycosis Fungoides · Columbia University
- Mar 2027A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides · Memorial Sloan Kettering Cancer Center
- Mar 2027ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome · Stanford University
Who these studies take
Of the 30 Mycosis Fungoides studies recruiting now, 25 (83%) set no upper age limit and 1 (3%) stop at 75 or younger. 2 (7%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (10%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (7%) | 2 (7%) |
| 18 | 28 (93%) | 28 (93%) |
| 30 | 29 (97%) | 29 (97%) |
| 40 | 29 (97%) | 29 (97%) |
| 50 | 29 (97%) | 29 (97%) |
| 65 | 30 (100%) | 30 (100%) |
| 75 | 30 (100%) | 30 (100%) |
| 85 | 29 (97%) | 29 (97%) |
Across all 447 studies, recruiting or not: 16% stop at 75 or younger and 8% at 65; 21% take children; 0% are for women only and <1% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Mycosis Fungoides studies take
Of 42 phase 2 interventional studies under Mycosis Fungoides, half reached primary completion within 64 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 56 mo28–80 · 29 studies | — | — |
| Phase 1/2 | 62 mo49–176 · 11 studies | — | — |
| Phase 2 | 64 mo39–111 · 42 studies | — | 64 mo40–119 · 33 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 15, 2026.
Newly registered2
Studies
Recruiting first, then most recently updated. Showing 50 of 447. Browse all 447 → or search them.
- Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary SyndromeNot yet recruitingNCT07926893Phase 11 country
- Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis ResearchRecruitingNCT001772681 country
- Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic LeukemiaNot yet recruitingNCT07682792Phase 21 country
- A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care MogamulizumabRecruitingNCT070031001 country
- Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceRecruitingNCT071325671 country
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT011376431 country
- A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid TumorsNot yet recruitingNCT07899632Phase 1/2
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin LymphomaRecruitingNCT04234048Phase 11 country
- A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin LymphomaRecruitingNCT07192471Phase 13 countries
- A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCLRecruitingNCT06854653Phase 24 countries
- Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell LymphomaRecruitingNCT04930653Phase 21 country
- Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.RecruitingNCT049041461 country
- Topical JAK-Inhibition of Early-Stage CTCLNot yet recruitingNCT07781449Phase 2
- Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell LymphomaRecruitingNCT03011814Phase 1/21 country
- Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis FungoidesRecruitingNCT05357794Phase 21 country
- Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)Not yet recruitingNCT07717580Phase 21 country
- A Study of Topical Duvelisib in Participants With Early-stage Mycosis FungoidesNot yet recruitingNCT07714187Phase 11 country
- Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid PapulosisRecruitingNCT062078121 country
- Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot TrialRecruitingNCT06580002Phase 21 country
- Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaRecruitingNCT06508463Phase 11 country
- Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary SyndromeRecruitingNCT04256018Phase 21 country
- Registry of Older Patients With CancerRecruitingNCT011378251 country
- Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell LymphomaNot yet recruitingNCT07658924Phase 2
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingNCT03017820Phase 11 country
- A Registry for People With T-cell LymphomaRecruitingNCT059781411 country
- Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis FungoidesRecruitingNCT05838599Early Phase 11 country
- Photopheresis in Early-stage Mycosis FungoidesRecruitingNCT05680558Phase 21 country
- A Study of VG712 in Patients With Mycosis FungoidesNot yet recruitingNCT07529405Phase 21 country
- A Study of Bexarotene Combined With Radiotherapy in People With Mycosis FungoidesRecruitingNCT05296304Phase 11 country
- Systemic Therapies in the Treatment of Cutaneous T-cell LymphomaRecruitingNCT065888681 country
- JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasRecruitingNCT06716658Phase 21 country
- ID Of Prognostic Factors In Mycosis Fungoides/Sezary SyndromeRecruitingNCT028482747 countries
- A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)Not yet recruitingNCT07213882Early Phase 1
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)RecruitingNCT070214951 country
- Long-term Assessment of Chlormethine Gel in Mycosis FungoidesNot yet recruitingNCT070466631 country
- Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCLRecruitingNCT063828441 country
- Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter StudyNot yet recruitingNCT06651203
- A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell LymphomaRecruitingNCT064366771 country
- The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult PatientsRecruitingNCT064215711 country
- Histopathological Changes in Mycosis FungoidesRecruitingNCT05904522Not applicable1 country
- Estimation of the Tissue and Serum Levels of Interleukin (IL) -35 in Mycosis Fungoides: a Case Control StudyRecruitingNCT058554601 country
- TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis FungoidesNot yet recruitingNCT05205902Phase 3
- Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell LymphomaActive, not recruitingNCT02520791Phase 12 countries
- Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary SyndromeActive, not recruitingNCT04652960Phase 11 country
- Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersActive, not recruitingNCT02978625Phase 21 country
- Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome PatientsActive, not recruitingNCT03587844Phase 21 country
- Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary SyndromeActive, not recruitingNCT04960618Phase 21 country
- Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell LymphomasActive, not recruitingNCT03598998Phase 1/21 country
- Study of Pembrolizumab (MK-3475) in Combination With RomidepsinCompletedNCT03278782Phase 1/21 country
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT011995621 country